Biosimilars With Foreign Comparator Data Could Open FDA To Criticism
Executive Summary
The agency’s biosimilars draft guidance documents contained a few surprising provisions, including a willingness to accept comparative data referencing a biologic product that is not approved in the U.S., a Covington and Burling attorney says.